{"page_content": "14Notes\n(a) The expenses related primarily to non-cash amortization of intangible assets acquired in business combinations.\n(b)The adjustment related to the Internal Revenue Service issuing final regulations that required us to recognize an additional year of the non-tax deductible branded \nprescription drug fee.\n(c) The adjustment related primarily to changing regulatory and reimbursement environments.\n(d)The tax effect of the adjustments between our GAAP and Adjusted results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets and non-cash interest expense associated with our convertible notes, whereas the tax impact of other adjustments, including the various legal proceedings, stock option expense and restructuring expense, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions.\n(e)The adjustments related to resolving certain non-routine transfer-pricing and acquisition-related issues with tax authorities as well as the impact related to certain prior period items excluded from adjusted earnings.Summary of Data\u2014Notes\nBusiness Profile\n(p)Corporate political contributions represent Amgen Inc.\u2019s US aggregate contributions among those states where these are permissible. Corporate political contributions to certain \ncandidates for state and local elected offices are permissible in accordance with applicable laws and Amgen policy. Outside the US, the rules governing corporate contributions to political parties and/or organizations vary by country. Amgen complies with all applicable laws and regulations in countries in which it has or intends to have a corporate presence or does business. Amgen adheres to a corporate policy that requires internal legal review before any contribution is made. Amgen considers making such contributions, where they are legally permissible, if the funds will be used to support education and engagement on science, technology, and innovation issues. Additional information may be found in the Corporate Governance section at www.amgen.com.\nAmgen Inc.\nReconciliation of GAAP Net Income to \u201cAdjusted\u201d Net Income (Unaudited) ($ in billions)\nResults for the years ended December 31, 2007 2011 2012 2013 2014 \nGAAP net income $3.078 $3.683 $4.345 $5.081 $ 5.158\nAdjustments to GAAP net income: \nAcquisition-related expenses (a) 0.402 0.342 0.470 1.008 1.546\nRestructuring and cost savings initiatives 0.739 0.162 0.347 0.071 0.596\nExpense resulting from clarified guidance on branded \nprescription drug fee (b) 0.129\nStock option expense 0.181 0.085 0.059 0.034 0.016\nExpense/(benefit) related to various legal proceedings 0.034 0.786 0.064 0.014 (0.003)\nNon-cash interest expense associated with our convertible notes0.219 0.143 0.140 0.012 -\nWrite-off of acquired in-process R&D 0.590 - - - - \nWrite-off of inventory (c) 0.090 - - - - \nOther 0.054 - - - - \n2.309 1.518 1.080 1.139 2.284\nTax effect of the above adjustments (d) (0.491) (0.331) (0.329) (0.376) (0.717)\nOther tax adjustments (e) (0.092) (0.012) 0.023 (0.030) (0.025)\n\u201cAdjusted\u201d net income $4.804 $4.858 $ 5.119 $5.814 $6.700\nReconciliation of GAAP R&D Expense to \u201cAdjusted\u201d R&D (Unaudited) ($ in billions)\nResults for the years ended December 31,  2007 2011 2012 2013 2014  \nGAAP R&D expense  $3.266 $ 3.167 $3.380 $4.083 $4.297\nAdjustments to GAAP R&D expense:  \nAcquisition-related expenses (a) ( 0.100 ) (0.028) (0.050) ( 0.142) (0.124)\nStock option expense (0.083) (0.035) (0.022) (0.012) (0.003)\nRestructuring and cost savings initiatives (0.019) (0.012) (0.012) - (0.049) \n\u201cAdjusted\u201d R&D expense $3.064 $ 3.116 $3.296 $3.929 $4.121(q)", "metadata": {"source": "NASDAQ_AMGN_2014.pdf", "page": 13, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}